Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EU Pharma Denies Skirting Rules On Pediatric Cancer Drug Development

This article was originally published in The Pink Sheet Daily

Executive Summary

The European pharmaceutical industry has refuted claims that manufacturers are exploiting a loophole in EU legislation to avoid running non-lucrative trials for pediatric oncology drugs.

Advertisement

Related Content

European Notebook Notes Arrival Of CHMP Minutes And Biosimilar MAbs
CHMP Clears Pierre Fabre’s Hemangiol For Children, Under Rarely Used Pediatric Pathway
EMA Approves Three Oncology Drugs, Rejects One
U.S. & EU Pediatric Drug Regulators Strive For Dialogue, Not Harmonization
EMEA Backs Conditional Marketing Of GSK’s Tykerb, Withdrawal Of Novartis’ Prexige In EU
EMEA Recommends Conditional European Marketing Authorization For Amgen's Vectibix
Europe’s Rx Kindergarten: Pediatric Development Plans Required Before Phase II

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS076826

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel